Two Sigma Securities’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
Other funds holding CRSP
Two Sigma Securities's CRSP Position: Q3 2026 in Review
Two Sigma Securities sold out of CRISPR Therapeutics (CRSP) in Q3 2026, closing a stake of 10,341 shares — an estimated $564K sold.
Two Sigma Securities first reported a position in CRSP in Q2 2021 and held it in 7 quarters. The position peaked at $687K in Q3 2022. 504 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.
- Two Sigma Securities reported no remaining CRISPR Therapeutics position as of Q3 2026 after selling out during the quarter.
- Two Sigma Securities sold 10,341 CRISPR Therapeutics shares in Q3 2026, an estimated $564K.
- Two Sigma Securities first reported a position in CRISPR Therapeutics in Q2 2021 and held it in 7 quarters.
- Two Sigma Securities's CRISPR Therapeutics position peaked at $687K in Q3 2022.
- 504 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.
Based on Two Sigma Securities's 13F filing for Q3 2026, filed 16 Nov 2026.